Roche completed the acquisition of Telavant Holdings from Roivant Sciences and Pfizer for $7.25bn.

Roche, a pharmaceutical and diagnostics company, completed the acquisition of Telavant Holdings, a company developing novel medicines to assist patients suffering from inflammatory and fibrotic disorders, from Roivant Sciences and Pfizer for $7.25bn. “We are pleased to announce the timely completion of the Telavant acquisition, and I am deeply grateful to everyone at Roivant and Telavant who worked tirelessly to develop RVT-3101, prepare for Phase 3, and execute this transaction. This transaction enables us to continue doing what we do best, at even greater scale: work creatively side by side with our partners on programs that could generate significant impact for patients in areas of high unmet need," Mayukh Sukhatme, Roivant President and CIO.